From Wikipedia, the free encyclopedia
Heterologous VSV- and Ad5-vectored Ebola vaccine
GamEvac-Combi
(Russian:
ГамЭвак-Комби
) is a heterologous VSV- and Ad5-vectored
Ebola vaccine
. There is also a version called
GamEvac
which is a homologous Ad5-vectored vaccine.
[1]
GamEvac-Combi was developed by
Gamaleya Research Institute of Epidemiology and Microbiology
. As of 2015
[update]
the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.
[2]
Description
[
edit
]
The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.
[3]
The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.
[4]
History
[
edit
]
GamEvac-Combi was licensed by the
Ministry of Health of the Russian Federation
for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.
[2]
See also
[
edit
]
References
[
edit
]
- ^
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, et al. (2017).
"Virus-Vectored Ebola Vaccines"
.
Acta Naturae
.
9
(3): 4?11.
doi
:
10.32607/20758251-2017-9-3-4-11
.
PMC
5662269
.
PMID
29104771
.
- ^
a
b
"Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations"
(PDF)
.
World Health Organization
. Retrieved
14 August
2020
.
- ^
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. (March 2017).
"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia"
.
Human Vaccines & Immunotherapeutics
.
13
(3): 613?620.
doi
:
10.1080/21645515.2016.1238535
.
PMC
5360131
.
PMID
28152326
.
- ^
Malvy D, McElroy AK, de Clerck H, Gunther S, van Griensven J (March 2019).
"Ebola virus disease"
.
Lancet
.
393
(10174): 936?948.
doi
:
10.1016/s0140-6736(18)33132-5
.
PMID
30777297
.